DDInter704 DDInter1618
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924]. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide. Romosozumab is marketed in the United States by Amgen under the brand name Evinity. Romosozumab was granted FDA approval on April 9,2019.
Everolimus {u} (Compound) upregulates {v} (Gene) FYN
FYN {u} (Gene) is bound by {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Blood creatinine increased {u} (Side Effect) is caused by {v} (Compound) Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus {u} (Compound) upregulates {v} (Gene) CRIP1
CRIP1 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is palliated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus {u} (Compound) upregulates {v} (Gene) KIT
KIT {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus {u} (Compound) downregulates {v} (Gene) PSMB8
PSMB8 {u} (Gene) is downregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Everolimus (Compound) upregulates FYN (Gene) and FYN (Gene) is bound by Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Everolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Everolimus (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Everolimus (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Everolimus (Compound) upregulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Everolimus (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is upregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Everolimus (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is palliated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Everolimus (Compound) upregulates KIT (Gene) and KIT (Gene) is bound by Dasatinib (Compound) and KIT (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Everolimus (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is downregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab